about us
IXICO is a leading provider of end to end medical imaging solutions to the pharmaceutical industry, from protocol design and site pre-qualification right through to image analysis and reporting.
We are a science-lead company that specializes in the quantitative use of medical imaging modalities to assess the impact of new therapies. We offer a unique combination of image acquisition know-how, state of the art analysis technology, and a streamlined computerized workflow system that can be adapted to customer needs and maintains a full electronic audit trail. We also have expertise in managing site logistics including pre-qualification, selection, training, rapid quality control feedback and monitoring.
IXICO can provide a comprehensive solution for imaging in clinical trials. Our team of in-house scientists, company founders, our network of world-renowned scientific and clinical advisers and experienced radiologists and nuclear medicine physicians, provides wide-ranging capability and a wealth of expertise.
IXICO is working with several of the worlds' largest pharmaceutical, biotechnology and healthcare companies in clinical trials, pre-clinical imaging, consultancy, and collaborative Research and Development. Our clinical trials activity involves projects from phase 0 to phase 3, working with sites and sponsors across the globe in therapeutic areas including neurodegeneration, oncology, rheumatoid arthritis, liver disease, respiratory disease and others . IXICO is based in Central London, close to some of the world's leading biomedical research and clinical trials units. We have close links with the top medical research universities in London, with Imperial College, University College London and King's College London all having a stake in the company.
IXICO is highly focused on meeting the quality and regulatory requirements of our customers, and our technology platform is designed from the outset with this in mind. Our Quality Management System is ISO9001:2000 certified, our procedures are ICH-GCP compliant, and our records are compliant with 21 CFR part 11.